{"member_organisations": "", "identification_number": "258845020786-10", "fields_of_interest": "Economy, finance and the euro, Trade, Competition, Business and Industry, Public Health", "head_office_address": "333 Lakeside Foster City", "full_time_equivalent_fte": "1,25", "person_with_legal_responsibility": "Milligan John", "industry_forums": "", "grants": "", "inter_groups": "", "eu_initiatives": "EU initiatives in relation to HIV/AIDS, Hepatitis B & C and oncology. Joint Action on HIV and co-infection prevention and harm reduction. \n \n- ATMP Regulation \n- EU IP policy \n- EU Relative Efficacy Assessment (EU REA) \n- EU research policy  \n- EU trade policy \n- Health Systems Performance Assessment \n- Health Technology Assessment & Market Access \n- Industrial policy \n- Outcomes-based healthcare systems \n- Paediatric Regulation \n- Sustainable Development Goals", "level_of_interest": "global", "organisation_name": "Gilead Sciences (GILD)", "belgium_office_post_code": "1831", "number_of_persons_involved": "3", "person_in_charge_of_eu_relations": "Mark Davis", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "(+32)24 01 35 50", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "Park Lane Culliganlaan 2", "no_geo_reference": true, "persons_accredited_for_access_to_european_parliament_premises": "ALBANO#Claire , MARK#Davis", "registration_date": "23/02/2016", "estimate_of_costs_absolute_amount": "", "website_address": "http://www.gilead.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "California", "membership": "AMCHAM EU: http://www.amchameu.eu/ \n \nTHE MENTOR GROUP", "head_office_post_code": "CA94404", "position": "Director, EU Affairs", "financial_year_start_date": "01/01/2017", "head_office_country": "United States", "number_of_ep_accredited_persons": "2", "relevant_communication": "Support to and participation in multi-stakeholder coalitions advocating for policy initiatives towards elimination of hepatitis C and promoting improved long term health outcomes for patients with HIV;  \n \nAn initiative with AMCHAM EU to identify policy options to improve the environment for life sciences innovation in the EU.", "financial_year_end_date": "01/12/2017", "estimate_of_costs_as_a_range": "300000-399999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company\u2019s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide.", "belgium_office_city": "Diegem", "head_office_phone": "(+1)6505743000"}